Editas Medicine Cleared to Start First-in-Human Trial of EDIT-401 for Hyperlipidemia
EDIT sits 69% above its 52-week low of $1.66.
Summary
Editas Medicine received approval to initiate the Phase 1/2 Strive trial of EDIT-401 in Australia, with new preclinical data showing durable ~90% LDL-C reduction. Initial safety data expected Q1 2027.
Key Events · Product Development and Regulatory · EDIT
-
EDIT-401 Cleared for First-in-Human Trial
Received HREC approval and completed TGA CTN process in Australia to initiate the Phase 1/2 Strive trial in patients with heterozygous familial hypercholesterolemia. Submission for review in New Zealand is also underway.
-
Durable Preclinical Efficacy Data
New preclinical data show ~90% LDL-C reduction maintained over 10 months in non-human primates, supporting potential for durable, lifelong benefit from a single dose.
-
AHA Presentation Scheduled
Oral presentation of EDIT-401 preclinical durability data at AHA Scientific Sessions 2026 on November 8, 2026, in Chicago.
-
Clinical Timeline
Initial safety and tolerability data expected in Q1 2027; Part 1 dose-finding enrollment completion with topline safety and efficacy data later in 2027.
Analysis · EDIT · Life Sciences
Editas Medicine received regulatory and ethics approval in Australia to begin the Phase 1/2 Strive trial of EDIT-401, its in vivo gene editing candidate for heterozygous familial hypercholesterolemia. This is the first clinical milestone for a program targeting a large cardiovascular market — over 70 million U.S. patients with hyperlipidemia and an estimated 1.2 million with HeFH. The company also disclosed new preclinical durability data showing ~90% LDL-C reduction maintained over 10 months in non-human primates, which will be presented at AHA Scientific Sessions on November 8, 2026. Initial safety and tolerability data are expected in Q1 2027, with topline efficacy data later in 2027. For a company with a market cap near $422 million and a stock price around $2.80, this approval validates the pipeline and provides a concrete near-term data catalyst.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.3% of the 1526 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EDIT was trading at $2.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $422.3M. The 52-week trading range was $1.66 to $4.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.